文献速递乳腺癌放疗

老年乳腺癌单用激素治疗与激素治疗联合放疗的人群研究

The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-03-01

该研究基于不列颠哥伦比亚1999-2009年70-79岁、1期雌激素受体阳性乳腺癌保乳术后患者,比较CALGB 9343发表前后辅助治疗模式。结果显示放疗联合激素治疗使用率未变(91% vs 89%,P=.4),单用激素治疗10年局部区域无复发生存率90%低于联合组98%(P=.01),但乳腺癌特异性生存率无差异(95% vs 96%,P=.2)。

要点

  • CALGB发表后放疗联合激素治疗使用率无显著变化(91% vs 89%,P=.4)。
  • 单用激素治疗10年局部区域无复发生存率90%,联合组98%(P=.01)。
  • 10年乳腺癌特异性生存率两组无差异(95% vs 96%,P=.2)。

核心结论

  • 患者结局与CALGB试验接近,提示其结果可推广至激素依从性典型的老年乳腺癌人群。
  • CALGB试验结果及实践指南未改变本人群中辅助放疗联合激素治疗的使用。

研究设计与样本

  • 基于人群的队列研究,纳入1999-2009年保乳术后70-79岁、1期雌激素受体阳性乳腺癌患者。
  • 比较CALGB发表前(1999-2003)与后(2005-2009)两个时期辅助治疗使用情况。
  • 采用Kaplan-Meier分析和Cox回归分析生存终点,Fine和Gray方法处理非乳腺癌死亡竞争风险。

主要发现

  • 放疗联合激素治疗使用率在CALGB发表前为91%(n=319),发表后为89%(n=403),P=.4。
  • 单用激素治疗组1年激素依从率为75%,4年为55%。
  • 10年局部区域无复发生存率联合组98%,单用组90%(P=.01)。
  • 10年乳腺癌特异性生存率联合组96%,单用组95%(P=.2)。
  • 组织学3级或淋巴血管侵犯患者无事件生存率更低;多因素分析中治疗类型不预测总生存(P=.3)。

关键数值与推荐

  • 激素依从性定义为配发处方激素治疗药物的80%。
  • 采用Charlson评分量化合并症。

临床怎么用

  • 在激素依从性典型的老年早期乳腺癌患者中,CALGB 9343结果可推广,支持单用激素治疗作为选项。
  • 放疗联合激素治疗可改善局部区域控制,但未显著改善乳腺癌特异性生存或总生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Cancer and Leukemia Group B (CALGB) 9343 trial randomized elderly women with estrogen receptor-positive, stage 1 breast cancer to receive either hormone therapy (HT) or HT and radiation therapy (HT-RT) after lumpectomy and showed no difference in survival. After this publication, a practice guideline made HT alone a standard treatment option in British Columbia. The subsequent population-based pattern of practice was studied. METHODS AND MATERIALS: All women aged 70 to 79 years, referred after lumpectomy from 1999 to 2009, with stage 1, estrogen receptor-positive breast cancer were identified. The use of adjuvant HT or HT-RT was evaluated in 2 eras: before (1999-2003) and after (2005-2009) the CALGB publication. The proportion receiving each treatment in these eras was determined. Kaplan-Meier analyses with Cox regression were used for survival endpoints. The Fine and Gray method was used with non-breast cancer death as a competing risk for event-free survival. The Charlson score was used to quantify comorbidity. Adherence was defined as dispensation of 80% of prescribed HT. RESULTS: HT-RT was used in 91% of patients before (n=319) and 89% of patients after (n=403) the CALGB publication (P=.4). In the HT-alone group, the rate of HT adherence was 75% at 1 year and 55% at 4 years. The 10-year locoregional recurrence-free survival rate was 98% with HT-RT and 90% with HT alone (P=.01), whereas the 10-year breast cancer-specific survival rate was 96% with HT-RT and 95% with HT alone (P=.2). Patients with grade 3 histology or lymphovascular invasion were more likely to have low event-free survival. On multivariate analysis, treatment type did not predict overall survival (P=.3). CONCLUSIONS: Our patient outcomes closely matched those of the CALGB trial, suggesting that its results are generalizable to a population of elderly breast cancer patients with typical HT adherence. The CALGB trial results, as well as the resulting practice guideline, did not change the use of adjuvant HT-RT in our population-based cancer program.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Nichol AM, Chan EK, Lucas S, et al. The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study. Int J Radiat Oncol Biol Phys. 2017. PMID: 28602413. doi:10.1016/j.ijrobp.2017.02.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。